**Core Concept**
Tacrolimus is a calcineurin inhibitor used as an immunosuppressive agent to prevent organ rejection in transplant patients. It acts by inhibiting the activation of T-lymphocytes, which play a key role in the immune response.

**Why the Correct Answer is Right**
Tacrolimus binds to FKBP-12, a cytosolic protein, forming a complex that inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation of the nuclear factor of activated T-cells (NFAT), which is essential for the transcription of IL-2 and other cytokines. As a result, the activation, proliferation, and differentiation of T-lymphocytes are suppressed. This mechanism of action is crucial in preventing graft rejection and autoimmune diseases.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect as it does not accurately describe the mechanism of action of tacrolimus. Tacrolimus does not work through the inhibition of cell membrane-bound enzymes.
**Option B:** This option is incorrect as it is a mechanism of action of sirolimus, a different immunosuppressive agent. Sirolimus inhibits the mammalian target of rapamycin (mTOR) pathway.
**Option C:** This option is incorrect as it describes the mechanism of action of cyclosporine, another calcineurin inhibitor. Cyclosporine binds to cyclophilin and inhibits calcineurin in a similar manner to tacrolimus.

**Clinical Pearl / High-Yield Fact**
Tacrolimus is known for its narrow therapeutic index, requiring frequent monitoring of blood levels to avoid nephrotoxicity and other adverse effects. Monitoring tacrolimus levels is crucial in preventing toxicity while maintaining adequate immunosuppression.

**Correct Answer:** D.